<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01692483</url>
  </required_header>
  <id_info>
    <org_study_id>CR100856</org_study_id>
    <secondary_id>212082PCR4003</secondary_id>
    <nct_id>NCT01692483</nct_id>
  </id_info>
  <brief_title>Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer</brief_title>
  <official_title>Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Metastatic Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Pharmaceutica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of abiraterone acetate in&#xD;
      male Filipino patients with advanced metastatic castration resistant prostate cancer (CRPC)&#xD;
      who have received prior chemotherapy containing a taxane.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (identity of assigned study drug will be known), observational study to&#xD;
      evaluate the safety and efficacy of abiraterone acetate in male Filipino patients with&#xD;
      advanced metastatic CRPC who have received prior chemotherapy containing a taxane.&#xD;
      Approximately 50 patients will be enrolled. Abiraterone acetate will be administered&#xD;
      according to the approved product insert with a low-dose glucocorticoid (prednisone or&#xD;
      prednisolone). Patient assessments will be based on the accepted clinical practice in the&#xD;
      Philippines. Patients will be monitored for 40 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor determined study is not required according to PFDA Circular 2013-004&#xD;
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants affected by an adverse event</measure>
    <time_frame>Up to 30 days after the last dose of study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with disease progression</measure>
    <time_frame>Baseline up to Week 40</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Neoplasms</condition>
  <arm_group>
    <arm_group_label>Abiraterone acetate plus prednisone</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone acetate</intervention_name>
    <description>Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily</description>
    <arm_group_label>Abiraterone acetate plus prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone or prednisolone 5 mg tablet taken orally twice daily</description>
    <arm_group_label>Abiraterone acetate plus prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male Filipino patients with advanced metastatic castration resistant prostate cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate without&#xD;
             neuroendocrine differentiation or small cell histology&#xD;
&#xD;
          -  Received at least 1 but not more than 2 cytotoxic chemotherapy regimens for metastatic&#xD;
             castration resistant prostate cancer (CRPC) (at least 1 regimen must have contained a&#xD;
             taxane such as docetaxel; if a chemotherapy regimen containing a taxane is used more&#xD;
             than once, this will be considered as 1 regimen)&#xD;
&#xD;
          -  Agrees to protocol-defined use of effective contraception&#xD;
&#xD;
          -  Laboratory values within protocol -defined parameters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious or uncontrolled co-existent non-malignant disease, including active and&#xD;
             uncontrolled infection&#xD;
&#xD;
          -  Abnormal liver function&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure &gt;=160 mmHg or diastolic blood&#xD;
             pressure &gt;=95 mmHg)&#xD;
&#xD;
          -  Active or symptomatic viral hepatitis or chronic liver disease&#xD;
&#xD;
          -  History of pituitary or adrenal dysfunction&#xD;
&#xD;
          -  Clinically significant heart disease as evidenced by myocardial infarction, or&#xD;
             arterial thrombotic events in the past 6 months, severe or unstable angina, or New&#xD;
             York Heart Association (NYHA) Class III or IV heart disease or left ventricular&#xD;
             ejection fraction of &lt;50% at baseline&#xD;
&#xD;
          -  Known brain metastasis&#xD;
&#xD;
          -  History of gastrointestinal disorders (medical disorders or extensive surgery) that&#xD;
             may interfere with the absorption of the study drug&#xD;
&#xD;
          -  Any acute toxicities due to prior chemotherapy or radiotherapy that have not resolved&#xD;
             to a NCI-CTCAE (Version 4.0) Grade of &lt;=1&#xD;
&#xD;
          -  Prior systemic treatment with an azole drug (eg, fluconazole, itraconazole,&#xD;
             ketoconazole) within 4 weeks of Cycle 1, Day 1&#xD;
&#xD;
          -  Condition or situation which, in the investigator's opinion, may put the patient at&#xD;
             significant risk, may confound the study results, or may interfere significantly with&#xD;
             patient's participation in the study&#xD;
&#xD;
          -  Participation in an investigational drug trial within 30 days prior to selection&#xD;
&#xD;
          -  Known hypersensitivity to abiraterone acetate, or to any of the components in the&#xD;
             formulation&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>is Janssen Pharmaceutica, Philippines Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutica, Philippines</affiliation>
  </overall_official>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>September 21, 2012</study_first_submitted>
  <study_first_submitted_qc>September 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2012</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate neoplasms</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Castration resistant prostate cancer</keyword>
  <keyword>Hormone refractory prostate cancer</keyword>
  <keyword>Abiraterone acetate</keyword>
  <keyword>Taxane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

